Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Alla S Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy Gotovkin, Shunji Takahashi, Daniella Ramone, Beata Maćkowiak-Matejczyk, Laura Polastro, Eva Maria Guerra Alia, Nicoletta Colombo, Yulia Makarova, Jeffrey C Goh, Kosei Hasegawa, Paulo Mora, Joanna Pikiel, Ratnesh Srivastav, Danny Rischin, Maria Jesús Rubio, Javier Perez, Suk Young Yoo, Bo Gao, Shaheda Jamil, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G Fury, Krishnansu S Tewari
Eur J Cancer 216 115146
摘要
摘要
AIM: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the phase III randomized study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9). METHODS: Cemiplimab (n = 304) or chemotherapy (n = 304) were administered every 3 weeks. The primary endpoint was overall survival (OS). Patients were included regardless of programmed cell death-ligand 1 (PD-L1) status. RESULTS: At a median follow-up of 47.3 months (data cut-off: April 20, 2023), median OS was 11.7 versus 8.5 months for patients treated with cemiplimab and chemotherapy, respectively (hazard ratio 0.67, 95 % confidence interval 0.56-0.80, p < .00001). OS benefit was seen in PD-L1 positive and negative populations, even though more patients with PD-L1 < 1 % (n = 92), had poor performance status in the cemiplimab arm than the chemotherapy arm (61.4 % vs 47.9 %). CONCLUSION: This final analysis confirms that cemiplimab maintains survival benefit compared with chemotherapy in recurrent cervical cancer after progression on first-line platinum therapy, regardless of PD-L1 expression. The safety profile was consistent with published data; incidences of adverse events were similar between cemiplimab and chemotherapy groups. These results support the use of second-line cemiplimab for patients with recurrent cervical cancer.
KM 提取结果
0 个 Figure · 0 个 KM 面板